These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36179946)

  • 1. Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy.
    Castillo-Regalado E; Ríos R; Aràjol C; Gely C; Márquez L; Calafat M; González-Muñoza C; Cañete F; Mesonero F; Guardiola J; Garcia-Planella E; Mañosa M; Domènech E
    Gastroenterol Hepatol; 2023 Mar; 46(3):164-170. PubMed ID: 36179946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease.
    Gjuladin-Hellon T; Gordon M; Iheozor-Ejiofor Z; Akobeng AK
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD008414. PubMed ID: 31220875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
    Gordon M; Taylor K; Akobeng AK; Thomas AG
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn's disease.
    Schoepfer AM; Bortolotti M; Pittet V; Mottet C; Gonvers JJ; Reich O; Fournier N; Vader JP; Burnand B; Michetti P; Froehlich F
    Aliment Pharmacol Ther; 2014 Oct; 40(8):930-7. PubMed ID: 25146487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-aminosalicylic acid dependency in Crohn's disease: a Danish Crohn Colitis Database study.
    Duricova D; Pedersen N; Elkjaer M; Jensen JK; Munkholm P
    J Crohns Colitis; 2010 Nov; 4(5):575-81. PubMed ID: 21122562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Azathioprine and mesalazine in the prevention of postsurgical recurrence of Crohn's disease: a retrospective study].
    Domènech E; Scala L; Bernal I; García-Planella E; Casalots A; Piñol M; Esteve-Comas M; Cabré E; Boix J; Gassull MA
    Gastroenterol Hepatol; 2004 Dec; 27(10):563-7. PubMed ID: 15574279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease.
    Thomson AB; Wright JP; Vatn M; Bailey RJ; Rachmilewitz D; Adler M; Wilson-Lynch KA
    Aliment Pharmacol Ther; 1995 Dec; 9(6):673-83. PubMed ID: 8824656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn's Disease Treated with Anti-metabolite Therapy.
    Picetti D; Kim J; Zhu W; Sandborn WJ; Jairath V; Singh S
    Dig Dis Sci; 2022 Jul; 67(7):3115-3123. PubMed ID: 34797442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting.
    Allocca M; Landi R; Bonovas S; Fiorino G; Papa A; Spinelli A; Furfaro F; Peyrin-Biroulet L; Armuzzi A; Danese S
    Digestion; 2017; 96(3):166-172. PubMed ID: 28903094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease.
    Gordon M; Naidoo K; Thomas AG; Akobeng AK
    Cochrane Database Syst Rev; 2011 Jan; (1):CD008414. PubMed ID: 21249709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
    Tromm A; Griga T; May B
    Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Wang Y; MacDonald JK; Hanauer S
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Propionyl-L-carnitine hydrochloride for treatment of mild to moderate colonic inflammatory bowel diseases.
    Merra G; Gasbarrini G; Laterza L; Pizzoferrato M; Poscia A; Scaldaferri F; Arena V; Fiore F; Cittadini A; Sgambato A; Franceschi F; Gasbarrini A
    World J Gastroenterol; 2012 Sep; 18(36):5065-71. PubMed ID: 23049215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease.
    Candia R; Bravo-Soto GA; Monrroy H; Hernandez C; Nguyen GC
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD012328. PubMed ID: 32746500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
    Florent C; Cortot A; Quandale P; Sahmound T; Modigliani R; Sarfaty E; Valleur P; Dupas JL; Daurat M; Faucheron JL; Lerebours E; Michot F; Belaiche J; Jacquet N; Soulé JC; Rothman N; Gendre JP; Malafosse M
    Eur J Gastroenterol Hepatol; 1996 Mar; 8(3):229-33. PubMed ID: 8724022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
    Clemett D; Markham A
    Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab for maintenance of remission in Crohn's disease.
    Townsend CM; Nguyen TM; Cepek J; Abbass M; Parker CE; MacDonald JK; Khanna R; Jairath V; Feagan BG
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012877. PubMed ID: 32413933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Hanauer S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
    Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
    World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index.
    Bodini G; Giannini EG; De Maria C; Dulbecco P; Furnari M; Marabotto E; Savarino V; Savarino E
    Dig Liver Dis; 2017 Feb; 49(2):175-180. PubMed ID: 27864028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.